<DOC>
	<DOC>NCT02352896</DOC>
	<brief_summary>EPI-743 in Leigh syndrome subjects that participated in previous EPI743-12-002 study.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome</brief_title>
	<detailed_description>To monitor the long-term safety and neurodevelopmental effects of EPI-743 on children who complete the EPI743-12-002 placebo controlled trial.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leigh Disease</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1. Diagnosis of Leigh syndrome with genetic confirmation 2. Completion of EPI74312002 protocol and initiation of treatment within 14 days of Month 12 Visit in EPI74312002 study 3. Patient or Patient's guardian able to consent and comply with protocol requirements 4. Continued abstention from supplements excluded in EPI74312002 study 5. Continued abstention from BotoxÂ® and for the duration of the study 1. Allergy to EPI743 or sesame oil 2. Allergy to vitamin E 3. Clinical history of bleeding or abnormal baseline PT/PTT 4. Hepatic insufficiency with LFTs greater than two times upper limit of normal 5. Renal insufficiency requiring dialysis 6. End stage cardiac failure 7. Fat malabsorption syndromes precluding drug absorption 8. Use of anticoagulant medications 9. Participation in other clinical research studies/taking other experimental agents 10. Participation in elective procedures that required sedation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Leigh syndrome</keyword>
	<keyword>Mitochondrial disorders</keyword>
	<keyword>EPI743</keyword>
	<keyword>Vincerinone</keyword>
</DOC>